UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 5 von 3585
Datensatz exportieren als...
BibTeX
Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta‐Analysis
Journal of cellular biochemistry, 2018-01, Vol.119 (1), p.511-523
Liu, Gui‐Feng
Li, Gui‐Jie
Zhao, Hang
2018
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Liu, Gui‐Feng
Li, Gui‐Jie
Zhao, Hang
Titel
Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta‐Analysis
Ist Teil von
Journal of cellular biochemistry, 2018-01, Vol.119 (1), p.511-523
Ort / Verlag
United States: Wiley Subscription Services, Inc
Erscheinungsjahr
2018
Quelle
Wiley Online Library Journals Frontfile Complete
Beschreibungen/Notizen
ABSTRACT Objective A network meta‐analysis was conducted to compare the efficacy and toxicity of different chemotherapy regimens in treating advanced or metastatic pancreatic cancer (PC). PubMed, Cochrane Library and EMBASE databases from inception to June 2016 were searched. A combination of direct and indirect evidences was referred to for calculating the weighted mean difference (WMD) or the odds ratio (OR) and to establish surface under the cumulative ranking (SUCRA) curves, so as to evaluate the efficacy and toxicity of different chemotherapy regimens in treating advanced or metastatic PC. Twenty randomized controlled trials were enrolled. Twelve chemotherapy regimens included Gemcitabine, S‐1 (Tegafur), Gemcitabine + Cisplatin, Gemcitabine + Capecitabine, Gemcitabine + S‐1, Gemcitabine + 5‐FU (5‐fluorouracil), Gemcitabine + Exatecan, Gemcitabine + Irinotecan, Gemcitabine + Nab‐paclitaxel, FOLFIRINOX (Oxaliplatin + Irinotecan + Fluorouracil + Leucovorin), Gemcitabine + Oxaliplatin, and Gemcitabine + Pemetrexed. Higher overall response rate (ORR) was observed in patients treated with the gemcitabine + S‐1 and FOLFIRINO regimens. Thrombocytopenia reduced in patients treated with the S‐1 regimen. The Gemcitabine + S‐1 and FOLFIRINO regimens had better short‐ and long‐term efficacies than the other regimens; S‐1 regimen had the lowest hematologic toxicity, while Gemcitabine + Nab‐paclitaxel, FOLFIRINOX, and Gemcitabine + Pemetrexed regimens had higher incidence of non‐hematologic toxicity among twelve chemotherapy regimens. The efficacy of Gemcitabine + S‐1 and FOLFIRINOX regimens may be better in treating patients with advanced or metastatic pancreatic cancer, while FOLFIRINOX and Gemcitabine + Pemetrexed regimens may have relatively higher incidence of toxicity than other regimens. J. Cell. Biochem. 119: 511–523, 2018. © 2017 Wiley Periodicals, Inc. A network meta‐analysis was conducted to compare the efficacy and toxicity of different chemotherapy regimens in the treatment of advanced or metastatic pancreatic cancer (PC). The results from this study indicate that Gemcitabine + S‐1 and FOLFIRINOX regimens may have better efficacy for treatment of patients with advanced or metastatic pancreatic cancer, while FOLFIRINOX and Gemcitabine + Pemetrexed regimens may have relatively higher incidence of toxicity than other regimens.
Sprache
Englisch
Identifikatoren
ISSN: 0730-2312
eISSN: 1097-4644
DOI: 10.1002/jcb.26210
Titel-ID: cdi_proquest_journals_1966884258
Format
–
Schlagworte
5-Fluorouracil
,
ADVANCED/METASTATIC PANCREATIC CANCER
,
Antineoplastic Combined Chemotherapy Protocols - adverse effects
,
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
,
BAYESIAN NETWORK MODEL/NETWORK META‐ANALYSIS
,
Cancer
,
Chemotherapy
,
CHEMOTHERAPY REGIMEN
,
Cisplatin
,
Clinical trials
,
Effectiveness
,
EFFICACY
,
Female
,
Gemcitabine
,
Humans
,
Incidence
,
Irinotecan
,
Male
,
Meta-analysis
,
Metastases
,
Metastasis
,
Neoplasm Metastasis
,
Oxaliplatin
,
Paclitaxel
,
Pancreatic cancer
,
Pancreatic Neoplasms - drug therapy
,
Pancreatic Neoplasms - metabolism
,
Pancreatic Neoplasms - pathology
,
Patients
,
RANDOMIZED CONTROLLED TRIALS
,
Tegafur
,
Thrombocytopenia
,
TOXICITY
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX